Where can I find BRNS's financial statements?

Barinthus Biotherapeutics plc (BRNS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for BRNS?

Barinthus Biotherapeutics plc (BRNS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does BRNS update its statements?

Barinthus Biotherapeutics plc files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

BRNS

Barinthus Biotherapeutics plc

NASDAQ·Biotechnology · Healthcare

$0.71$0.06+8.68%

After hours·$0.71+0.00%

Market cap$28.86M·Market closed·Aug 26 8:00 PM UTC

USD · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$268.00K−94.4%	$44.70M+16,580.2%	$802.00K−98.2%	$14.97M+1,766.5%	$0.00−100.0%
Cost of revenue	—	—	—	—	$5.86M
Gross profit	$268.00K+102.8%	$44.70M+16,580.2%	$802.00K−98.2%	$14.97M+1,766.5%	−$5.86M−139.1%
Research & development	$16.37M+13.8%	$41.11M+151.1%	$41.41M+0.7%	$38.25M−7.6%	$25.56M−33.2%
General & administrative	$25.12M+139.7%	$6.39M−74.5%	$39.84M+523.1%	$29.67M−25.5%	$40.83M+37.6%
SG&A (combined)	$25.12M+139.7%	$6.39M−74.5%	$39.84M+523.1%	$29.67M−25.5%	$40.83M+37.6%
Other operating expenses	$4.00M+127.8%	$1.24M−69.0%	$3.46M+179.1%	$15.02M+333.9%	−$18.06M−220.3%
Total operating expenses	$45.49M+334.1%	$48.74M+7.2%	$84.72M+73.8%	$82.94M−2.1%	$48.34M−41.7%
Operating income	−$45.22M−125.6%	−$4.04M+91.1%	−$83.91M−1,976.6%	−$67.97M+19.0%	−$54.19M+20.3%
Interest income	$2.00K	$3.10M+155,050.0%	$2.88M−7.3%	$2.68M−6.9%	$1.96M−26.9%
Interest expense	$2.67M−25.9%	$19.00K−99.3%	$28.00K+47.4%	$53.00K+89.3%	$51.12K−3.5%
Other income / (expense), net	−$5.92M−368.1%	$4.89M+182.6%	$7.39M+51.1%	$6.74M−8.8%	−$14.60M−316.5%
Income before tax	−$51.14M−186.7%	$850.00K+101.7%	−$76.52M−9,102.6%	−$61.23M+20.0%	−$68.79M−12.4%
Income tax expense	−$28.00K−129.5%	−$4.47M−15,867.9%	−$3.08M+31.2%	−$44.00K+98.6%	−$2.18M−4,854.7%
Net income	−$50.87M−187.3%	$5.34M+110.5%	−$73.35M−1,473.0%	−$61.07M+16.7%	−$66.58M−9.0%

EPS (basic)	−$1.37+38.8%	$0.14+110.2%	−$1.91−1,464.3%	−$1.55+18.8%	−$1.64−5.8%
EPS (diluted)	−$1.37+38.8%	$0.14+110.2%	−$1.91−1,464.3%	−$1.55+18.8%	−$1.64−5.8%
Weighted avg shares (basic)	37,189,000	37,248,000	38,386,000	39,348,000	40,527,218
Weighted avg shares (diluted)	37,189,000	38,169,000	38,386,000	39,348,000	40,527,218

Depreciation & amortization	$602.00K+189.4%	$4.32M+618.1%	$5.43M+25.6%	$5.80M+6.8%	$5.85M+0.8%
EBITDA	−$47.87M−189.1%	$5.19M+110.8%	−$71.07M−1,468.7%	−$55.37M+22.1%	−$62.90M−13.6%

Frequently Asked Questions About BRNS

Where can I find BRNS's financial statements?: Barinthus Biotherapeutics plc (BRNS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for BRNS?: Barinthus Biotherapeutics plc (BRNS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does BRNS update its statements?: Barinthus Biotherapeutics plc files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

$268.00K−94.4%

$44.70M+16,580.2%

$802.00K−98.2%

$14.97M+1,766.5%

$0.00−100.0%

Cost of revenue

—

$5.86M

Gross profit

$268.00K+102.8%

$44.70M+16,580.2%

$802.00K−98.2%

$14.97M+1,766.5%

−$5.86M−139.1%

Research & development

$16.37M+13.8%

$41.11M+151.1%

$41.41M+0.7%

$38.25M−7.6%

$25.56M−33.2%

General & administrative

$25.12M+139.7%

$6.39M−74.5%

$39.84M+523.1%

$29.67M−25.5%

$40.83M+37.6%

SG&A (combined)

$25.12M+139.7%

$6.39M−74.5%

$39.84M+523.1%

$29.67M−25.5%

$40.83M+37.6%

Other operating expenses

$4.00M+127.8%

$1.24M−69.0%

$3.46M+179.1%

$15.02M+333.9%

−$18.06M−220.3%

Total operating expenses

$45.49M+334.1%

$48.74M+7.2%

$84.72M+73.8%

$82.94M−2.1%

$48.34M−41.7%

Operating income

−$45.22M−125.6%

−$4.04M+91.1%

−$83.91M−1,976.6%

−$67.97M+19.0%

−$54.19M+20.3%

Interest income

$2.00K

$3.10M+155,050.0%

$2.88M−7.3%

$2.68M−6.9%

$1.96M−26.9%

Interest expense

$2.67M−25.9%

$19.00K−99.3%

$28.00K+47.4%

$53.00K+89.3%

$51.12K−3.5%

Other income / (expense), net

−$5.92M−368.1%

$4.89M+182.6%

$7.39M+51.1%

$6.74M−8.8%

−$14.60M−316.5%

Income before tax

−$51.14M−186.7%

$850.00K+101.7%

−$76.52M−9,102.6%

−$61.23M+20.0%

−$68.79M−12.4%

Income tax expense

−$28.00K−129.5%

−$4.47M−15,867.9%

−$3.08M+31.2%

−$44.00K+98.6%

−$2.18M−4,854.7%

Net income

−$50.87M−187.3%

$5.34M+110.5%

−$73.35M−1,473.0%

−$61.07M+16.7%

−$66.58M−9.0%

EPS (basic)

−$1.37+38.8%

$0.14+110.2%

−$1.91−1,464.3%

−$1.55+18.8%

−$1.64−5.8%

EPS (diluted)

−$1.37+38.8%

$0.14+110.2%

−$1.91−1,464.3%

−$1.55+18.8%

−$1.64−5.8%

Weighted avg shares (basic)

37,189,000

37,248,000

38,386,000

39,348,000

40,527,218

Weighted avg shares (diluted)

37,189,000

38,169,000

38,386,000

39,348,000

40,527,218

Depreciation & amortization

$602.00K+189.4%

$4.32M+618.1%

$5.43M+25.6%

$5.80M+6.8%

$5.85M+0.8%

EBITDA

−$47.87M−189.1%

$5.19M+110.8%

−$71.07M−1,468.7%

−$55.37M+22.1%

−$62.90M−13.6%